Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | CES1 | P23141 | 2/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5286030 | 0.98 | ALOX5 (0.41) | ALOX5CES2CES1KEAP1SLC6A2 | |
| SCHEMBL29337167 | 0.83 | — | — | |
| SCHEMBL3341284 | 0.83 | — | — | |
| SCHEMBL12993068 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL17497697 | 0.82 | ALOX5 (0.40) | ALOX5CES2CES1KEAP1SLC6A2 | |
| SCHEMBL4444118 | 0.80 | ALOX5 (0.42) | ALOX5CES2CES1KEAP1SLC6A2 | |
| SCHEMBL11544964 | 0.79 | HPGD (0.44) | ALOX5CES2CES1KEAP1NPC1 | |
| SCHEMBL3229012 | 0.78 | NPC1 (0.53) | ALOX5CES2CES1KEAP1SLC6A2 | |
| SCHEMBL14525329 | 0.78 | NPC1 (0.53) | ALOX5CES2CES1KEAP1SLC6A2 | |
| SCHEMBL23695275 | 0.77 | CA2 (0.43) | ALOX5CES2CES1KEAP1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3546066-B1 | AMPHOTERIC DISSOCIATION ION EXCHANGE MEDIUM, ITS USE, AND SEPARATION CAPACITY CALIBRATION METHOD | CHONGQING BOLANYING BLY BIOTECHNOLOGY CO LTD CHINA (CN) | 2021-01-20 | — | — | EP | claimed |
| US-20190291095-A1 | AMPHOTERIC DISSOCIATION ION EXCHANGE MEDIUM AND USES THEREOF AND METHOD FOR CALIBRATING SEPARATION CAPACITY THEREOF | CHONGQING BOLANYING BLY BIOTECHNOLOGY CO LTD (CN) | 2019-09-26 | — | — | US | claimed |
| WO-2022131741-A1 | ISOXAZOLIDINE DERIVATIVE COMPOUND AND USE THEREOF | 보로노이바이오 주식회사 | 2022-06-23 | — | — | WO | disclosed |
| US-11358136-B2 | Amphoteric dissociation ion exchange medium and uses thereof and method for calibrating separation capacity thereof | CHONGQING BOLANYING (BLY) BIOTECHNOLOGY CO., LTD. (CN) | 2022-06-14 | — | — | US | disclosed |
| EP-3546066-B1 | AMPHOTERIC DISSOCIATION ION EXCHANGE MEDIUM, ITS USE, AND SEPARATION CAPACITY CALIBRATION METHOD | CHONGQING BOLANYING BLY BIOTECHNOLOGY CO LTD CHINA (CN) | 2021-01-20 | — | — | EP | disclosed |
| US-20200376480-A1 | AMPHOTERIC DISSOCIATION ION EXCHANGE MEDIUM AND USES THEREOF AND METHOD FOR CALIBRATING SEPARATION CAPACITY THEREOF | CHONGQING BOLANYING (BLY) BIOTECHNOLOGY CO., LTD. (CN) | 2020-12-03 | — | — | US | disclosed |
| EP-3546066-A1 | AMPHOTERIC DISSOCIATION ION EXCHANGE MEDIUM, APPLICATION METHOD, AND SEPARATION CAPACITY CALIBRATION METHOD | Chongqing Bolanying (BLY) Biotechnology Co., Ltd., China (CN) | 2019-10-02 | — | — | EP | disclosed |
| US-20190291095-A1 | AMPHOTERIC DISSOCIATION ION EXCHANGE MEDIUM AND USES THEREOF AND METHOD FOR CALIBRATING SEPARATION CAPACITY THEREOF | CHONGQING BOLANYING BLY BIOTECHNOLOGY CO LTD (CN) | 2019-09-26 | — | — | US | disclosed |
| US-20110213029-A1 | 3,4-Di-Substituted Cyclobutene-1,2-Diones as CXC-Chemokine Receptor Ligands | SCHERING CORPORATION (US) | 2011-09-01 | — | — | US | disclosed |
| EP-1951643-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | Auspex Pharmaceuticals Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007062119-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20050272930-A1 | Process for the prepation of 3-hydroxy-(2-thienyl)propanamines | HEMS WILLIAM | 2005-12-08 | — | — | US | disclosed |
| CN-1671685-A | Process for the preparation of 3-hydroxy- (2-thienyl) propanamines | DEGUSSA (DE) | 2005-09-21 | — | — | CN | disclosed |
| EP-1523479-A1 | PROCESS FOR THE PREPARATION OF 3-HYDROXY-(2-THIENYL)PROPANAMINES | Degussa AG (DE) | 2005-04-20 | — | — | EP | disclosed |
| WO-2004031168-A2 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF OPTICALLY ACTIVE 3-AMINO-1-(2-THIENYL)-1-PROPANOL DERIVATIVES | LONZA AG (CH) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004011452-A1 | PROCESS FOR THE PREPARATION OF 3-HYDROXY-(2-THIENYL)PROPANAMINES | DEGUSSA AG (DE) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213029-A1 | 3,4-Di-Substituted Cyclobutene-1,2-Diones as CXC-Chemokine Receptor Ligands | CCR1, ACKR3, CXCR1 | ALOX5 428/4885CES2 2560/4885CES1 2009/4885 |
| US-20050272930-A1 | Process for the prepation of 3-hydroxy-(2-thienyl)propanamines | PNMT, HPD, HRH3 | ALOX5 3067/4885CES2 1859/4885CES1 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.